Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Ironwood Pharmaceuticals | 669.13 Mn | 590.00 Mn | - | 26.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.97% |
| Mar 31, 2026 | -3.74% |
| Dec 31, 2025 | 22.07% |
| Sep 30, 2025 | -7.30% |
| Jun 30, 2025 | -13.98% |
| Mar 31, 2025 | -43.65% |
| Dec 31, 2024 | 36.06% |
| Sep 30, 2024 | -59.73% |
| Jun 30, 2024 | -26.04% |
| Mar 31, 2024 | -28.14% |
| Dec 31, 2023 | 33.10% |
| Sep 30, 2023 | -26.02% |
| Jun 30, 2023 | -256.29% |
| Mar 31, 2023 | 139.08% |
| Dec 31, 2022 | 0.70% |
| Sep 30, 2022 | 34.56% |
| Jun 30, 2022 | 42.50% |
| Mar 31, 2022 | 37.74% |
| Dec 31, 2021 | 157.21% |
| Sep 30, 2021 | 32.27% |